查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771483

美國主髂動脈阻塞性疾病治療市場：市場規模、佔有率、趨勢分析（按設備類型、程序和最終用途）、細分市場預測（2025-2030 年）

U.S. Aorto-iliac Occlusive Disease Treatment Market Size, Share & Trends Analysis Report By Device Type, By Procedure, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場規模預計在2024年達到7.166億美元，預計2025年至2030年的複合年成長率為5.4%。周邊動脈疾病（PAD）盛行率的上升、政府相關舉措的不斷增加以及技術的進步正在推動市場成長。例如，飛利浦於2024年11月在美國啟動了THOR IDE臨床試驗，以評估一種結合雷射動脈粥狀硬化斑塊切除術和血管內碎石術的新型混合導管系統。

該設備用於治療周邊動脈疾病 (PAD) 和主髂動脈疾病中常見的嚴重鈣化病變。路易斯安那州南方心血管研究所首次成功實施的患者手術證明了該設備在簡化複雜干預措施和改善手術結果方面的潛力。越來越多的政府舉措推動市場成長 根據 2023 年 6 月發表的一篇 Congress.Gov報導，美國政府透過推出《綜合動脈和靜脈 (ARC) 法案》，在加強周邊動脈疾病(PAD)（主髂動脈阻塞性疾病的主要原因）的早期發現和管理方面邁出了重要一步。該立法提案對《社會保障法》進行修訂，旨在允許被確定為高風險的醫療保險和醫療補助受益人免費接受 PAD 篩檢。

有針對性的診斷方法包括踝臂指數 (ABI) 測試和動脈雙功能掃描，這些方法對於識別周邊動脈疾病 (PAD) 和評估主髂動脈區域的疾病嚴重程度至關重要。 ARC 法案授權在 2024 年至 2028 年期間每年撥款 600 萬美元，旨在探索改善早期診斷和及時干預、減輕晚期阻塞性疾病負擔以及增加對髂動脈支架置入術和重組療法等標靶治療方案需求的可能性。該舉措旨在促進預防保健，並支持更廣泛地獲得基本血管醫療服務。

美國門診手術中心 (ASC) 和辦公室實驗室 (OBL) 的激增大大促進了血管介入手術量的增加，包括主髂動脈阻塞性疾病。這些中心為傳統醫院設施提供了一種經濟高效且方便的替代方案，可迅速治療患者、降低開銷並允許患者和醫生靈活安排時間。因此，髂動脈介入治療，如球囊血管成形術、置入術和動脈粥狀硬化動脈粥狀硬化斑塊切除術，擴大在 ASC 和 OBL 中進行，特別是對於患有早期到中期疾病的患者。這些微創手術通常可以在門診進行，非常適合這些中心，因為縮短恢復時間和降低手術風險是這些中心的首要任務。優惠的報銷政策也支持向此類中心的轉變，使它們成為護理提供者和付款人的首選地點。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章美國主動脈髂動脈阻塞性疾病（髂動脈疾病）治療市場：依設備類型估計與趨勢分析

  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場（依儀表板、設備類型）
  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場：按設備類型分類的容量分析
  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場收益（以設備類型）
  • 血管內裝置
    • 球囊血管成形術裝置
    • 動脈粥狀硬化斑塊切除系統
    • 支架
  • 手術設備

第5章美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場：依程序的估計與趨勢分析

  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場，儀表板，依程序
  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場：按治療程序進行的數量分析
  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場收益（依治療方式）
  • 血管內手術
    • 球囊血管成形術
    • 初次支架置入術
    • 吻合支架
    • 覆膜血管支架
    • 主動脈腔內修復術（EVAR）
  • 混合手術
  • 外科手術

第6章。美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場：按最終用途的估計和趨勢分析

  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場（依最終用途分類）
  • 美國主動脈髂動脈阻塞性疾病（髂動脈疾病）治療市場：依最終用途分類的銷售分析
  • 美國主髂動脈阻塞性疾病（髂動脈疾病）治療市場（按收益和最終用途）
  • 醫院
  • 門診設施
  • 其他

第7章 競爭態勢

  • 主要製造商的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要企業市場佔有率分析（2024年）
  • 公司簡介
    • BD
    • Abbott
    • Boston Scientific Corporation
    • WL Gore &Associates, Inc.
    • Medtronic
    • Cook
    • Terumo Corporation
    • Getinge AB
Product Code: GVR-4-68040-614-6

Market Size & Trends:

The U.S. aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 716.6 million in 2024 and is projected to grow at a CAGR of 5.4% from 2025 to 2030. Increasing PAD incidence, rising government initiatives, and technological advancements drive market growth. For instance, in November 2024, Philips recently launched the THOR IDE clinical trial in the U.S. to evaluate a novel hybrid catheter system that combines laser atherectomy and intravascular lithotripsy.

The device is designed to treat severely calcified lesions commonly found in PAD and aorto-iliac disease. The first successful patient procedure, conducted at the Cardiovascular Institute of the South in Louisiana, demonstrates the potential for this device to streamline complex interventions and improve procedural outcomes. Increasing government initiatives drive market growth. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs.

Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, which are critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

The proliferation of ambulatory surgical centers (ASCs) and office-based labs (OBLs) across the U.S. significantly contributes to the growth in procedural volumes for vascular interventions, including those for aorto-iliac occlusive disease. These facilities offer a cost-effective and convenient alternative to traditional hospital settings, enabling quicker patient turnaround, reduced overhead costs, and enhanced scheduling flexibility for both patients and physicians. As a result, iliac artery interventions-such as balloon angioplasty, stenting, and atherectomy are increasingly being performed in ASCs and OBLs, especially for patients presenting with early to moderate stages of the disease. These minimally invasive procedures can often be completed on an outpatient basis, making them well-suited to these settings where shorter recovery times and lower procedural risk are prioritized. The shift toward these centers is also supported by favorable reimbursement policies, making them a preferred site of care for providers and payers.

U.S. Aorto-iliac Occlusive Disease Treatment Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aorto-iliac occlusive disease (iliac disease) treatment market report based on device type, procedure, and end-use:

  • Device Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Endovascular Devices
    • Balloon Angioplasty Devices
    • Atherectomy Systems
    • Stents
    • Self-Expanding Stents
    • Balloon-Expandable Stents
    • Covered Stent Grafts
    • Bifurcated Aortic Stent Grafts
  • Surgical Devices
  • Procedure Outlook (Revenue, USD Million, 2018 - 2030)
  • Endovascular Procedures
    • Balloon Angioplasty
    • Primary Stenting
    • Kissing Stents
    • Covered Stent Grafts
    • Endovascular Aortic Repair (EVAR)
  • Hybrid Procedures
  • Open Surgical Procedures
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Outpatient Facilities
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Device Type
    • 1.2.2. Procedure
    • 1.2.3. End Use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Volume price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Device Type outlook
    • 2.2.2. Procedure outlook
    • 2.2.3. End Use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of peripheral artery disease (PAD)
      • 3.2.1.2. Advancements in endovascular technologies
      • 3.2.1.3. Shift towards in minimally invasive procedures
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product recalls
      • 3.2.2.2. Clinical complexity and procedural risks
  • 3.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Estimates & Trend Analysis

  • 4.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Dashboard
  • 4.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Movement Analysis
  • 4.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Device Type, Revenue
  • 4.4. Endovascular Devices
    • 4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.2. Balloon Angioplasty Devices
      • 4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.3. Atherectomy Systems
      • 4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.4. Stents
      • 4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.2. Self-expanding Stents
        • 4.4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.3. Balloon-expandable Stents
        • 4.4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.4. Covered stent grafts
        • 4.4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.5. Bifurcated aortic stent grafts
        • 4.4.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5. Surgical Devices
    • 4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Estimates & Trend Analysis

  • 5.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Dashboard
  • 5.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Movement Analysis
  • 5.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Procedure, Revenue
  • 5.4. Endovascular Procedures
    • 5.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Balloon Angioplasty
      • 5.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Primary Stenting
      • 5.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.4. Kissing Stents
      • 5.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.5. Covered Stent Grafts
      • 5.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.6. Endovascular Aortic Repair (EVAR)
      • 5.4.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Hybrid Procedures
    • 5.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Surgical Procedures
    • 5.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Dashboard
  • 6.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Movement Analysis
  • 6.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by End Use, Revenue
  • 6.4. Hospitals
    • 6.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Outpatient Facilities
    • 6.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. BD
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Abbott
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Boston Scientific Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. W. L. Gore & Associates, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Medtronic
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Cook
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Terumo Corporation
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Getinge AB
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of secondary sources
  • Table 3 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by device type, 2018 - 2030 (USD Million)
  • Table 4 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by procedure, 2018 - 2030 (USD Million)
  • Table 5 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new services
  • Table 12 Key companies undergoing partnerships
  • Table 13 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. aorto-iliac occlusive disease (iliac disease) treatment market segmentation
  • Fig. 7 Market snapshot, 2024
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market driver relevance analysis (current & future impact)
  • Fig. 10 Market restraint relevance analysis (current & future impact)
  • Fig. 11 Swot analysis, by factor (political & legal, economic, and technological)
  • Fig. 12 Porter's five forces analysis
  • Fig. 13 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Outlook Key Takeaways
  • Fig. 14 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Movement Analysis
  • Fig. 15 Endovascular devices market, 2018 - 2030 (USD Million)
  • Fig. 16 Balloon angioplasty devices market, 2018 - 2030 (USD Million)
  • Fig. 17 Atherectomy systems market, 2018 - 2030 (USD Million)
  • Fig. 18 Stents market, 2018 - 2030 (USD Million)
  • Fig. 19 Self-expanding stents market, 2018 - 2030 (USD Million)
  • Fig. 20 Balloon-expandable stents market, 2018 - 2030 (USD Million)
  • Fig. 21 Covered stent grafts market, 2018 - 2030 (USD Million)
  • Fig. 22 Bifurcated aortic stent grafts market, 2018 - 2030 (USD Million)
  • Fig. 23 Surgical devices market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure outlook key takeaways
  • Fig. 25 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure movement analysis
  • Fig. 26 Endovascular procedures market, 2018 - 2030 (USD Million)
  • Fig. 27 Balloon angioplasty market, 2018 - 2030 (USD Million)
  • Fig. 28 Primary stenting market, 2018 - 2030 (USD Million)
  • Fig. 29 Kissing stents market, 2018 - 2030 (USD Million)
  • Fig. 30 Covered stent grafts market, 2018 - 2030 (USD Million)
  • Fig. 31 Endovascular aortic repair (EVAR) market, 2018 - 2030 (USD Million)
  • Fig. 32 Hybrid procedures market, 2018 - 2030 (USD Million)
  • Fig. 33 Open surgical procedures market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use outlook key takeaways
  • Fig. 35 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use movement analysis
  • Fig. 36 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 37 Outpatient facilities market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Strategy framework